12:00 AM
 | 
Jun 12, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/9 cls
Array (ARRY) C.E. Unterberg, Towbin Katherine Kim New Buy 15% $8.95
Kim set a $14 target. She believes the company's ARRY-334543, a dual EGFR/HER-2 inhibitor in Phase Ia testing to treat solid tumors, could be a "best in class" compound.
BioMarin (BMRN; SWX:BMRN) Pacific Growth Liana Moussatos New

Read the full 393 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >